0.90 USD
▼-0.06-6.22%
盘后 0.91 +1.04%
2026-09-15
市值
$254.33M
市盈率
—
EPS
-0.11
股息率
—
52 周区间
0.81 – 3.20
成交量
5.78M
Beta
0.19
目标价
3.80
52W 低 0.8152W 高 3.20
价格走势
公司简介
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia...